Key result
Low molecular weight heparin is the drug of choice for VTE during pregnancy, whereas warfarin is contraindicated in the first trimester and perinatal period due to teratogenicity and bleeding risks.
Why the study?
What is the safety profile and optimal management strategy for antithrombotic therapy during pregnancy?
What is the safety profile and optimal management strategy for antithrombotic therapy during pregnancy?
LMWH is preferred for VTE management in pregnancy due to its safety profile, whereas pregnant patients with mechanical heart valves require complex, staged anticoagulation management to balance maternal and fetal risks.
No takes yet. Share an insight, caveat, or question.
Supports LMWH preference for pregnancy VTE; leaves open optimal valve strategies needing prospective validation.
Ageno et al. (2004) conducted a review in Pregnancy requiring antithrombotic therapy. Antithrombotic therapy (Warfarin, UFH, LMWH) was evaluated. Low molecular weight heparin is the drug of choice for VTE during pregnancy, whereas warfarin is contraindicated in the first trimester and perinatal period due to teratogenicity and bleeding risks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: